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Abstract: Insoluble aggregates staining positive to amyloid
dyes are known histological hallmarks of different neurode-
generative disorders and of type II diabetes. Soluble oligo-
mers are smaller assemblies whose formation prior to or
concomitant with amyloid deposition has been associated
to the processes of disease propagation and cell death.
While the pathogenic mechanisms are complex and differ
from disease to disease, both types of aggregates are impor-
tant biological targets subject to intense investigation in
academia and industry. Here we review recent advances in
the fundamental understanding of protein aggregation that
can be used on the development of anti-amyloid and anti-
oligomerization drugs. Specifically, we pinpoint the chemical
kinetic aspects that should be attended during the develop-
ment of high-throughput screening assays and in the hit val-
idation phase. The strategies here devised are expected to
establish a connection between basic research and pharma-
ceutical innovation.
1. Introduction
Over the recent years, protein aggregation has been in the
limelight of drug discovery: on the one hand, several projects
targeting amyloid aggregates in neurodegenerative disorders
have been discontinued.[1] On the other hand, smaller protein
aggregates—the soluble oligomers—are increasingly surfacing
as major culprits of neurotoxicity and pathogenic spread.[2] Co-
incidently with this paradigm shift,[3] encouraging results have
been obtained by the first generation of anti-oligomerization
drug candidates in clinical trials of Alzheimer’s disease and Par-
kinson’s disease.[4]
The long and costly workflow leading to the discovery of
new drugs has in its basis methods of high-throughput screen-
ing (HTS) of active compounds (known as “hits”) that can be
further developed into drug precursors (known as “leads”) or
used as “chemical probes” to validate a given biological
target.[5] Targeted HTS approaches rely on in vitro protein ag-
gregation assays having well-defined reaction components and
high reproducibility indexes.[6] However, deciphering the exact
mode of action of aggregation inhibitors is not a trivial task on
account of the possible pathways (Figure 1a) and multiple ele-
mentary steps (Figure 1b) that might be implicated. It may
occur, for instance, that large amounts of stable soluble oligo-
mers are formed without their presence being directly detect-
ed by amyloid-specific probes such as thioflavin-T (ThT) or by
turbidimetric methods.[7]
Widely applied in the study of amyloid aggregation mecha-
nisms,[10] chemical kinetic analysis is gradually being estab-
lished as a promising tool for the systematic screenings of
both anti-amyloid and anti-oligomerization compounds.[11] An
important step in this direction was taken by defining the ref-
erence kinetic behavior expected for generic nucleation-and-
growth processes of phase transition.[12] When no other path-
way is present, the formation of insoluble species begins with
the elementary step of primary nucleation and then proceeds
through the occurrence of the autocatalytic steps of secondary
nucleation and growth. Thermodynamic equilibrium is attained
when the chemical potential of the solution equals that of the
insoluble fraction. At that point, the concentration of protein
monomer (C) corresponds to the protein solubility (C* ), and so
the driving force for phase transition represented by supersa-
Figure 1. Aggregation pathways during amyloid fibril formation. a) Protein
monomers establish a thermodynamic equilibrium with soluble oligomers
that are either on- or off-pathway to produce amyloid fibrils. Off-pathway
oligomers can undergo phase transition processes leading to the formation
of different types of precipitates,[8] and then act as heterogeneous nucleants
of amyloid fibrils. b) Reaction steps participating in the amyloid pathway.
Green glows represent an increase in the mass of amyloid fibrils.[9]
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turation DC ¼ C @ C* (or in dimensionless form s ¼ DC=C* ) is
zero. After expressing supersaturation in terms of the normal-
ized reaction conversion (a),
s ¼ s0 1@ að Þ ð1Þ
The following closed-form solution of the mass balance equa-
tions is obtained for unseeded reactions (a0 ¼ 0):[12]
a ¼ 1@ 1
kb exp katð Þ@ 1½ Aþ 1 ð2Þ
where ka and kb are determined by the elementary steps that
increase the mass of insoluble aggregates (Figure 1b). Sigmoi-
dal progress curves comprising an initial lag phase followed by
an exponential phase and a plateau phase are expected in the
cases of slow primary nucleation,[6, 13] for which the values of kb
are lower than ' 0:01.[7, 12] In turn, fast primary nucleation pro-
cesses (kb > 0:01) give rise to hyperbolic progress curves that
are also observed during seeded aggregation assays (see sec-
tion 2.). Protein aggregation modulators can be screened
based on kinetic signatures standing out from the standard be-
havior expected by Equation (2).[7] This is valid for both on-
and off-pathway inhibition as it is shown next for the case of
amyloid fibril formation.
2. The Amyloid Aggregation Assay
Amyloid fibrils have a characteristic cross-beta-sheet structure
that is detectable upon binding to Congo red, ThT and thiofla-
vin-S (ThS) dyes.[11a,14] Although amyloid aggregation can be
followed by other spectrophotometric techniques,[15] thioflavin
fluorescence is adequate for HTS kinetic assays that require
low sample volume, high signal-to-noise ratios and high repro-
ducibility.[6,11b] The use of this probe is not without pitfalls aris-
ing from non-amyloid binding, reduced sensibility to early (on-
pathway) aggregates and fluorescence self-quenching.[16] As
with other assays employing light-based detection methods,
orthogonal validation using different output reporters is re-
quired in order to identify false positives and fluorescence arti-
facts.[17] The development and optimization of HTS assays aims
at rightfully interrogate a given therapeutic target using minia-
turized formats of 96-well, 384-well or 1536-well microplates.[18]
Since amyloid nucleation is a stochastic process,[19] some varia-
bility between replicate experiments is expectable even when
homogeneous, highly pure protein samples are used.[20] This is
detrimental for the quality of the HTS assay usually character-
ized in terms of the Z 0 factor (Figure 2a) taking into account
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the means (m) and standard deviations (SD) of positive and
negative controls. A Z 0 factor > 0:5 indicates a good degree of
separation between controls.[21] To improve reproducibility,
pre-formed fibrils (or “seeds”) can be added to the initial solu-
tion to bypass the primary nucleation step.[22] The drawback of
seeded assays is their insensibility to aggregation inhibitors
specifically targeting non-templated nucleation. Other alterna-
tives designed to accelerate fibrillation through the use of
glass beads, vigorous agitation, high temperature, low pH and/
or denaturating additives only remotely reproduce the biologi-
cal medium.[22] Heterogeneous nucleants such as lipid micelles,
can be used to mimic the cell membrane and disease-propa-
gating exosomes,[23] and at the same time catalyze protein ag-
gregation with improved reproducibility.[24] In principle, seed-
ing is not expected to influence the ThT fluorescence increase
(DFF), which is an important thermodynamic measurable
(Figure 2a) proportional to the initial supersaturation
DC0 ¼ C0 @ C* . The kinetic influence of seeding is accounted
by analyzing the normalized progress curves (Figure 2b) and
the half-life coordinates t50 and v50 (Figure 2c). The fundamen-
tal definitions of t50 and v50 are expressed in terms of apparent
rate constants k0a and k
0
b,
[12]
t50 ¼
1
k0a
ln
1
k0b
þ 1
. -
ð4aÞ
v50 ¼
k0a
4
k0b þ 1ð Þ ð4bÞ
which in turn are influenced by the initial fraction of seeds a0
(computed in relation to the total polymerizable protein, DC0):
k0a ¼ ka 1þ a0ð Þ ð5aÞ
k0b ¼
kb þ a0
1þ a0 ð5bÞ
For unseeded reactions (a0 ¼ 0), k0a ¼ ka and k0b ¼ kb. As it fol-
lows from eq 2, otherwise sigmoidal progress curves
(kb < 0:01) will develop hyperbolic shapes if > 1% of pre-
formed fibrils are added to the initial solution (k0b > 0:01).
3. Recognizable Modulators
Timely reviews on protein aggregation modulation were put
forward by for example, Doig and Derreumaux,[25] Eisele
et al. ,[26] and Velander et al. ,[27] where different classifications of
inhibitors are adopted based on mechanistic and physico-
chemical considerations. Here we make a shorter selection of
examples that are representative of the modes of action sum-
marized in Figure 3. For the sake of simplicity each mechanism
is illustrated separately, although synergistic and antagonistic
effects may take place simultaneously. The selected examples
are listed in Table 1.
Purely kinetic inhibitors (Figure 3a) slow down the rate of
fluorescence increase without changing the final fluorescence,
which is a value indicative of the amount of amyloid fibrils pro-
duced. This is achieved through kinetic inhibition of any of the
steps of primary nucleation, secondary nucleation or fibril elon-
gation that increase the amyloid-specific signal (indicated by
green arrows in Figures 1 and 3). Fluorination of the hydropho-
bic residues valine or phenylalanine of the LVFFD peptide in-
creases the duration of the lag phase of Ab42 aggregation
without significantly changing the normalized aggregation
rate v50 or the value of the total fluorescence increase F1.
[28]
Therefore, the fluorinated peptides are considered kinetic in-
hibitors acting upon the step of primary nucleation.[28]
The lead compound CLR01 is a molecular tweezer that spe-
cifically binds to lysine residues thus disrupting important in-
teractions for protein aggregation.[29] The impact of CLR01 on
ThT progress curves changes according to the amyloidogenic
protein being studied; in the case of Ab40 aggregation, a ten-
fold excess added during the exponential and plateau phases
induced an evident disaggregating effect manifested by a pro-
gressive loss of amyloid signal.[30] This trend, which has also
been observed during incubation of Ab42 with brazilin,[31] cor-
responds to the kinetic signature of fibril disaggregators (Fig-
ure 3b).
By preventing fragmentation, fibril stabilization (Figure 3c)
might reduce prion-like spreading of small aggregates within
and between cells, as demonstrated for seeded spreading of
Ab and tau using animal models of Alzheimer’s disease.[26, 32]
Tight binding fibril stabilizers might also decrease the amyloid
Figure 2. Example showing an optimized a-synuclein aggregation assay. A
good separation between positive and negative controls was achieved by
adding 0.2 mm of pre-formed fibrils (or “seeds”) to the reaction mixture con-
sisting of 2 mm a-synuclein in 50 mm sodium phosphate pH 7.5, 200 mm
NaCl and 70 mm ThT (Z. S#rk#ny and P. M. Martins, personal communication).
a) Symbols: ThT fluorescence (F) measured over time in a 384-well plate,
each well containing 0.2 mm of seeds in the presence (blue) and absence
(gray) of soluble a-synuclein. A Z 0 factor of 0.66 was obtained using mean
values (m, dashed lines) and standard deviations (SD, shaded areas corre-
spond to 3> SD) calculated for the F measurements at time point 187 hours
(FF) in 192 positive controls (red symbols) and 192 negative controls (green
symbols). b) Amyloid conversion calculated as the normalized fluorescence
increase (a ¼ DF=DFF) taking as reference the instantaneous negative con-
trols (DF ¼ F @ m@). c) Mean values of amyloid conversion ((a, symbols), t50
(vertical dashed line) and v50 (sloping dashed line) calculated from the ex-
perimental data in (b). Shaded areas represent m: SD intervals.
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solubility and redirect the equilibrium from potentially more
toxic, small oligomers to amyloid fibrils (large green arrow in
Figure 3c).[7, 8, 12] This hypothesis has been explored through
the development of orange G-related compounds bound to
the steric zipper Ab16-21 structure.[33]
According to the supersaturation-dependence of ka and kb,
protein-specific modulation of solubility (C* ) is an attractive
approach to change the kinetics—and not only the thermody-
namics—of amyloid fibril formation. This can be achieved
using as target the amyloid pharmacophore of the soluble pro-
tein (Figure 3c) or, alternatively, the metastable oligomers (Fig-
ures 3d,e). Monomer stabilizers (Figure 3d) selectively increase
the solubility of the target protein, shifting the on- and off-
pathway equilibria towards the dissociation of oligomers. As
the result of the higher C* values, less amyloid fibrils are pro-
duced and lower fluorescence signals are expected at the end
of the assay (Figure 3d, middle) ; because the values of super-
saturation decrease, larger t50 values and lower v50 values are
also expectable (Figure 3d, bottom). Monomer stabilizers and
oligomer binders (Figure 3e) are not clearly distinguishable
from simple progress curves analysis if the mode of action of
the latter type of inhibitor comprises the stabilization of the
oligomeric assembly. This is because as the amyloidogenic pro-
tein is sequestered into the oligomeric state, the pool of avail-
able monomers is depleted leading to the train of events that
culminates in lower DF1 values and slower aggregation kinet-
ics. Mimics of the islet amyloid polypeptide (IAPP) synthesized
with N-methylated amide bonds were shown to inhibit the ag-
gregation of IAPP and Ab40 by a common mechanism of stabi-
lization of protein monomers and nontoxic oligomers.[34] Ac-
cordingly, the IAPP mimics are included in the categories of
protein and oligomer stabilizers (Figures 3d,e, respectively).
The stabilization of the transthyretin (TTR) tetramer by tafami-
dis (Vyndaqel ; Pfizer),[35] and by the repurposed drugs diflunis-
al[36] and tolcapone[37] inhibits the formation of amyloid depos-
its by preventing the dissociation of the tetramer into aggrega-
tion competent TTR monomers. Commonly referred as “kinetic
stabilizers’,[26] these compounds are here classified as oligomer
stabilizers (Figure 3e) to avoid confusion with the kinetic inhib-
itors having no thermodynamic effects on aggregation (Fig-
ure 3a).
The new evidences associating non-amyloidogenic oligo-
mers to the pathogenesis of neurodegenerative diseases allow
us to anticipate a renewed interest in oligomer breakers (Fig-
ure 3e) as a therapeutic hypothesis to remodel toxic assem-
blies into nontoxic species. In the example of Figure 3e, the
aggregation equilibrium is redirected to the formation of more
amyloid fibrils (Figure 3e, top) and at faster rates (Figure 3e,
bottom). Other scenarios are, however, possible in which the
amyloid pathway is not favored either because protein solubili-
ty is concomitantly increased or, as in the case of Ab42 aggre-
gation in the presence of the N-methylated peptide inhibitor
SEN304,[38] other nontoxic pathways are elicited.
Figure 3. The different types of aggregation modulators recognizable by the
amyloid aggregation assay. Each panel gives the mode of action (top, car-
toon symbols as in Figure 1) and the kinetic signatures (middle and bottom)
of each type of modulator; the progress curves represent the fluorescence
(F) increase (middle) and the amyloid conversion (bottom) in the absence
(solid lines) and presence (dashed lines) of test compound. The theoretical
curves were computed using Equation (2) and assuming (i) ka and kb propor-
tional to DC0=C* , and (ii) F proportional to the product DC0a.
[9, 43] a) Kinetic
inhibitors (associated to lower ka and kb values) decrease the rates of pri-
mary nucleation, secondary nucleation or fibril elongation (dashed arrows in
the cartoon). b) Disaggregators provoke the dissociation of fibrils into solu-
ble protein (red arrow in the cartoon). c) Fibril stabilizers decrease the values
of solubility (C* ) through stabilization of amyloid fibrils (large green arrow)
and might prevent fibril breakage (dashed blue arrow) d) Monomer stabiliz-
ers decrease the aggregation propensity (dashed orange and green arrows)
by inducing higher values of C* . e) Oligomer binders may either stabilize or
inhibit the formation of off-pathway oligomers, thereby decreasing or in-
creasing the effective monomer concentration and the corresponding super-
saturation value. f) Apparent inhibitors non-specifically alter the solution
properties, which may reduce the thermodynamic propensity for aggrega-
tion (by reducing DC0) but do not affect ka and kb (as DC0=C* remains con-
stant).[42]
Table 1. Examples taken from the literature illustrating the different types of aggregation modulators presented in Figure 3.
Modulator Representative Examples
Kinetic Inhibitor - Peptide LVFFD with fluorinated valine or phenylalanine during Ab42 aggregation.[28]
Disaggregator - CLR01 during Ab40 aggregation.[30]
- Brazilin during Ab42 aggregation.[31]
Fibril Stabilizer - Orange G-related compounds bound to the steric zipper Ab16-21 structure.[33]
Monomer Stabilizer - Mimics of IAPP synthesized with N-methylated amide bonds during the aggregation of IAPP and Ab40.[34]
Oligomer Binder - Tafamidis,[35] diflunisal[36] and tolcapone[37] during the aggregation of TTR.
- N-Methylated peptide inhibitor SEN304 during the aggregation of Ab42.[38]
Apparent Inhibitor - Thermodynamic effects provoked by interfaces or by the addition of salts during amyloid aggregation.[42]
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Changing the ionic strength of amyloidogenic solutions by
the addition (or removal) of salts can have a dramatic influence
on amyloid aggregation in vitro,[39] which is understood in
terms of the role of solubility in determining the rate and
extent of protein self-assembly.[7, 8, 12,40] These modulation ef-
fects are considered “apparent” (Figure 3 f) since they are un-
specific and tend to be buffered in cells and tissues media. Ap-
parent inhibitors that solely alter the activity coefficient of the
protein will originate superimposed progress curves if repre-
sented in normalized ThT fluorescence units (Figure 3 f,
bottom); this has been previously illustrated using published
data of Pronchik et al.[41] on the influence of hydrophobic inter-
faces on a-synuclein aggregation.[42] It should be noted that
the superimposition of normalized curves does not necessarily
imply that the test compound should be discarded. In fact,
Figure 3 does not exhaustively cover all possible mechanisms
of inhibition, but instead it seeks to summarize the major
types of modulators that can be identified by kinetic assays.
4. Primary Screenings, Secondary Screenings,
Hit Validation
Having set up a reproducible amyloid aggregation assay does
not guarantee that large numbers (> 105) of chemical com-
pounds can be efficiently assessed during HTS campaigns, es-
pecially if several days are required to measure full progress
curves. In these cases, a primary screening strategy can be de-
vised to limit the measurement frequency to the initial,
middle, and final points of the reaction (Figure 4). The corre-
sponding values F0, F50 and FF (Figure 4a) can be followed in
multiple plates simultaneously without advanced robotic sys-
tems being necessarily required. Positive hits stand out by
showing DF50=DFF ratios significantly different from the value
of 0.5 expected in the absence of modulation effects and for
apparent inhibitors (Figure 4b).
The 3-point aggregation assay can be used on the identifica-
tion of positive hits as well as on the preliminary characteriza-
tion of the putative inhibition mechanism. This requires the
analysis of the DF50=DFF ratio (Figure 5a) but also of DFF
values obtained in the presence and absence of the test com-
pound (Figure 5b). Kinetic inhibitors, for example, are expected
to originate values of DF50=DFF # 0:5 with no major impact
on the values of DFF (Figure 5c). The progress curves charac-
teristic of monomer and soluble oligomer stabilizers are not
easily distinguishable (see previous representations in Figur-
es 3d and 3e), and both are associated to markedly low values
of DF50=DFF and of DFF (Figure 5d). Conversely, very high
values of DF50=DFF and of DFF may indicate the cases of fibril
stabilizers and of oligomer breakers (Figure 5e).
In the same way that Figure 3 did not cover all possible in-
hibition mechanisms, Figure 5 gives a limited number of exam-
ples that can be identified by the 3-point screening assay. As
expectable, this initial analysis is not free from ambiguities as
exemplified in Figure 5 by cell B3, whose result can be ascribed
Figure 4. A possible strategy for primary screenings based on initial, mid-
point and endpoint measurements. a) The midpoint (t50) and endpoint (tF)
instants are defined beforehand taking into account the control progress
curve (solid line) characterizing the amyloid aggregation assay. Rather than
continuously measuring the full progress curve in the presence of test com-
pounds (dashed line), only the fluorescence increase at time-points t50
(DF50 ¼ F50 @ F0) and tF (DFF ¼ FF @ F0), respectively, are measured. b) Nega-
tive results elicited by, e.g. , fluorogenic compounds and apparent inhibitors
can be identified by values of the DF50=DFF ratio close to 0.5.
Figure 5. Possible readouts expected from the 3-point aggregation assay. a
and b) Illustrative example of an arbitrary 96-well microplate with the assay
output represented in terms of (a) the DF50=DFF ratios and (b) the impact
on the value of DFF ; different colors indicate different values of the readout
as indicated in the colorbars. Cells B3, B9, G7 and H11 are positive hits iden-
tified in (a) and then further analyzed in (b). c to e) The combinations of
DF50 and DFF values highlighted in (a) and in (b) apply to sigmoidal prog-
ress curves (lines) obtained in the absence (solid lines) and presence
(dashed lines) of (c) kinetic inhibitors, (d) soluble protein stabilizers, and (e)
fibril stabilizers/oligomer breakers. Horizontal dashed lines in (d) and (e) rep-
resent cases of undefined aggregation suppressors.
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to fibril stabilizers, oligomer breakers (both cases represented
in Figure 5e) or undefined aggregation suppressors (Fig-
ure 5d). To clarify this type of doubts, the initial hits—including
the undefined results—have to undergo the next round of
screenings based on dose-response, full progress curve analy-
sis.
In addition to the conventional representation of a over
time, amyloid aggregation curves are conveniently plotted in
log-linear a= 1@ að Þ vs. time coordinates so as to detect devia-
tions from the standard behavior expected by Equation (2).
These deviations, which are dealt in detail elsewhere,[7] are evi-
denced by non-linear trends arising after the initial lag phase.
The relative importance of off-pathway aggregation generally
increases as the curvature of the ln a= 1@ að Þð Þ representation
gets more pronounced. Therefore, distinguishing between sim-
ilar signatures of aggregation modulators such as fibril stabiliz-
ers and oligomer breakers (Figures 3c,e), or monomer stabiliz-
ers and oligomer stabilizers (Figures 3d,e) is possible by repre-
senting the reaction coordinates in the modified log-linear
scale. Dose-response analyses of the assay measurables t50 ,
v50 and DFF are important to establish the potency of the se-
lected compounds by means of the half-maximal inhibitory
concentration (IC50) and the half-maximal effective concentra-
tion (EC50) parameters.
[44] Yet, to answer the question on
whether the right target has been reached, the relationships
DFF, v50 , and t50 vs. protein concentration at constant com-
pound concentration should also be looked in detail. In recent
contributions we demonstrated that these scaling laws reflect
the relative composition of monomers and soluble oligomers
measured by direct methods.[9, 43] Specifically, a direct corre-
spondence between the end-point amyloid signal and the ini-
tial concentration of monomer can be expected when no off-
pathway oligomers are present (Figure 6a) or when their disso-
ciation is much slower than the formation of amyloid fibrils
(Figure 6b). This correspondence will not be observed if the
oligomerization equilibrium is reversed by the gradual vanish-
ing of protein monomers provoked by the amyloidogenic
pathway (Figure 6c). Examples of refractory and reversible off-
pathway oligomerization were observed during the aggrega-
tion of human insulin and ataxin-3, respectively.[9,43]
The oligomerization pathway can be further probed by ana-
lyzing the influence of protein concentration on the half-life
coordinates. The scaling laws of v50 (Figure 7a) and t50 (Fig-
ure 7b) show marked deviations from linearity in the presence
of slowly dissociating oligomers, with unconventional scaling
exponents (g) being admissible independently of the dominant
step(s) of amyloid fibrillation (Figure 7b). Within the context of
HTS secondary screenings, the analysis of protein concentra-
tion scaling laws in the presence and absence of test com-
pounds is an effort worth making in order to discriminate
which pathway is being affected and by which mechanisms.
Hit results found by indirect kinetic assays need to be vali-
dated by a combination of experimental methods capable of
characterizing both quantitatively and qualitatively the target
aggregates. The available options can be roughly categorized
into spectroscopic, chromatographic, calorimetric, light scatter-
ing, microscopy and high-resolution techniques, which have
Figure 6. The scaling laws of final florescence with total protein concentra-
tion (CT) provide insights into off-pathway oligomerization—Figure repro-
duced under the terms of the CC BY 4.0 license from Silva et al. .[43] The initial
distributions of monomer and total protein (left side) influences the end-
point scaling laws (right side). The correspondence between the initial and
final stages is direct if (a) no oligomerization pathway is present or (b) oligo-
merization is irreversible, and indirect if (c) oligomerization is fully reversible.
Green lines describe cases of protein solubility values C* ¼ 0 (solid lines)
and C* > 0 (dashed lines).
Figure 7. Highly diverse kinetic scaling laws are expected depending on the
relative importance of off-pathway aggregation. The scaling laws of (a) v50
and (b) t50 change according to the initial degree of oligomerization and the
rate at which off-pathway oligomers dissociate (color bar). The variability of
the scaling exponents (g) cannot be explained if only on-pathway mecha-
nisms are considered. Figure adapted under the terms of the CC BY 4.0 li-
cense from Silva et al.[43] assuming the cases of predominant secondary nu-
cleation and hyperbolic initial distributions of monomers vs. total protein.
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been subject of updated reviews by for example, Poklar
Ulrih,[45] Pryor et al. ,[46] and Renaud et al. .[47] The application of
these techniques may either confirm or deny the first indica-
tions resulting from the amyloid aggregation assay. Illustrating
this, Wobst et al.[48] employed circular dichroism (CD) to detect
changes in the secondary structure of tau protein and to con-
firm that the green tea polyphenol (@)-epigallocatechin gallate
(EGCG) prevents the formation of b-sheet-rich tau oligomers.
On the other hand, Middleton et al.[49] used isotope labelling
and two-dimensional infrared spectroscopy to show how ag-
gregation inhibitors may function by complex structural pro-
cesses that are not detected by ThT fluorescence. Infrared
nanospectroscopy has recently been used to characterize oli-
gomeric and fibrillar species during amyloid formation of
ataxin-3.[50] Nuclear Magnetic Resonance (NMR) spectroscopy
can provide high-resolution structural information as that used
to unveil the ligand binding details of an anti-amyloidogenic
compound (phthalocyanine tetrasulfonate) to a-synuclein. Al-
ternatively, NMR spectroscopy can be utilized to follow the for-
mation of intermediate and off-pathway oligomers by periodi-
cally collecting the 1H NMR spectra associated to monomer de-
pletion. This has been done while studying the effect of Cu2+
on a-synuclein aggregation,[51] and to demonstrate the ability
of EGCG to shift off-pathway aggregation of Ab40.[52] Solid-
state NMR,[53] together with X-ray microcrystallography,[54] X-ray
fiber diffraction[55] and cryo-electron microscopy[56] further en-
larged the resolution limits of amyloid structures,[57] and con-
tributed to reveal morphological differences between amyloid
fibrils generated in vitro or in the brain.[58] With the recent ad-
vances in instrumentation, high intensity synchrotron sources,
robotics/automation, speed of data processing, etc. , some of
the benchmark technologies are now being applied in de
novo screenings of aggregation modulators. For example, in-
hibitors of human IAPP and Ab40 aggregation were identified
by ion mobility spectrometry-mass spectrometry using ThT
fluorescence monitoring as a control method to detect possi-
ble hydrophobic interactions that become lost in the gas
phase.[59] The scope of light scattering techniques is also ex-
panding from proof-of-concept to high-throughput applica-
tions as in the cases of dynamic light scattering (DLS) for size
distribution monitoring,[60] and small angle X-ray scattering
(SAXS) for characterizing the oligomeric equilibrium of non-ag-
gregated samples.[61] In another approach, a time-resolved fluo-
rescence resonance energy transfer (FRET) assay was devel-
oped to screen 7:46> 105 compounds and identify 56 hits
that markedly inhibit a-synuclein and several phenyl-benzoxa-
zol compounds that promote a-synuclein aggregation (proag-
gregators).[62] Important for subsequent phases of hit to lead
optimization,[5, 18] cell-based assays based on phenotypic and
cytotoxicity readouts have also been used for compound
screening purposes in the identification of IAAP aggregation
inhibitors.[63]
5. Conclusions and Perspectives
Despite all the advances in the understanding of protein ag-
gregation kinetics, the translation of this knowledge into new
practical tools for drug discovery has been limited. We believe
that this scenario is about to change on account of two rea-
sons both connected with the key role played by soluble oligo-
mers in the process of amyloid fibril formation. First, there is a
growing interest in anti-oligomerization compounds as a possi-
ble therapeutic strategy to block the progression of neurode-
generative disorders and amyloidoses. Second, soluble oligo-
mers, and particularly non-amyloidogenic off-pathway oligo-
mers leave distinctive signatures in amyloid aggregation
curves and scaling laws that help distinguishing which type of
protein aggregates are being targeted. In the present work we
reviewed the different mechanisms of action of known anti-
amyloid and anti-olgomerization compounds and showed how
their effect can be identified in reaction progress curves. The
systematization of this analysis led us to propose the 3-point
aggregation assay for the primary screening of large libraries
of chemical compounds based on ThT fluorescence readouts
at the starting-point, (supposed) half-life and (supposed) end-
point instants of the reaction. We also reviewed the chemical
kinetic tools available for the secondary screening and hit vali-
dation phases, which may involve the analysis of full progress
curves represented in modified coordinates and the analysis of
DFF, v50 , and t50 scaling laws.
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